[6-K] Taiwan Semiconductor Manufacturing Company Ltd. Current Report (Foreign Issuer)
Taiwan Semiconductor Manufacturing Company Limited disclosed that TSMC Global Ltd.'s board adopted a written-consent resolution on August 12, 2025 to approve a capital increase of not more than US$10 billion to be contributed by Taiwan Semiconductor Manufacturing Co., Ltd. The action is conditional and subject to approval of the competent authorities. The filing identifies this decision as a board-level corporate action taken without a meeting and does not include financial statements, timing, or further transactional details.
Taiwan Semiconductor Manufacturing Company Limited披露,TSMC Global Ltd. 的董事会已在2025年8月12日通过一项书面同意决议,批准由台湾半导体制造股份有限公司出资的不超过100亿美元的增资。该行动具有条件性,须获得主管机关的批准。备案将此决定标识为在无会议的情况下作出的董事会层面的公司行动,并未包含财务报表、时间安排或其他交易细节。
- Board authorization for a significant capital increase (up to US$10 billion) demonstrates a clear, formal corporate decision.
- Funding source identified as Taiwan Semiconductor Manufacturing Co., Ltd., indicating internal support for the capital move.
- The capital increase is conditional and requires approval from competent authorities, so it is not finalized.
- No timing, terms, or financial details (such as use of proceeds or impact on equity) are disclosed in the filing.
Insights
Board authorized a large, conditional capital injection of up to US$10 billion.
The board of TSMC Global Ltd. approved a capital increase not exceeding US$10 billion, to be funded by Taiwan Semiconductor Manufacturing Co., Ltd., which is a material corporate finance action by size alone. Because the contribution is subject to regulatory approval, the transaction remains conditional and incomplete.
What to watch: confirmation of regulatory approvals and any disclosed timing or terms.
The decision was taken by written consent, indicating board-level agreement without a formal meeting.
The board adopted the resolution by written consent on August 12, 2025, which is a legally valid method for corporate action where permitted. The filing states the capital increase is contingent on approval from competent authorities, highlighting regulatory review is required before funds are committed.